NASDAQ:PXMD PaxMedica 8/9/2023 Earnings Report ProfileEarnings History PaxMedica EPS ResultsActual EPS-$4.08Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APaxMedica Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APaxMedica Announcement DetailsQuarterDate8/9/2023TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile PaxMedica Earnings HeadlinesPaxMedica, Inc. (PXMD) - Yahoo FinanceJuly 11 at 3:41 PM | nz.finance.yahoo.comStudy Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD PatientsSeptember 23, 2024 | msn.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 14 at 2:00 AM | Porter & Company (Ad)BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884KSeptember 3, 2024 | msn.comYale Study Unravels Autism, Brain Growth PatternsSeptember 1, 2024 | msn.comPaxMedica, Inc.: PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness InfectionAugust 27, 2024 | finanznachrichten.deSee More PaxMedica Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PaxMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PaxMedica and other key companies, straight to your email. Email Address About PaxMedicaPaxMedica (NASDAQ:PXMD) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for neuropsychiatric and mood disorders. Leveraging proprietary formulation technologies, the company seeks to improve the safety, tolerability and dosing convenience of established therapeutic agents. By optimizing drug delivery profiles, PaxMedica aims to address unmet needs in patient populations suffering from serious central nervous system conditions. The company’s pipeline comprises three programs in various stages of development. Its lead candidate is a long-acting injectable formulation designed to provide sustained plasma levels for the management of schizophrenia. A second program is an extended-release oral therapy targeting major depressive disorder, while a third preclinical program is focused on a novel approach to core behavioral features of autism spectrum disorders. PaxMedica collaborates with academic medical centers and contract research organizations to advance these assets through clinical and preclinical studies. Founded in 2018 and headquartered in New York City, PaxMedica also maintains research operations in Massachusetts and pursues partnerships in Europe. After its initial public offering in 2021, the company has continued to build a leadership team of seasoned professionals in neuroscience R&D, regulatory affairs and global commercialization. The board of directors consists of industry veterans from the biotechnology and pharmaceutical sectors, guiding the company’s strategic growth and development efforts.Written by Jeffrey Neal JohnsonView PaxMedica ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025)Bank of America (7/16/2025)The Goldman Sachs Group (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
